20.500.12556/DiRROS-19072 Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results. NSCLC non-small cell lung cancer locally advanced immunotherapy chemoradiotherapy nedrobnocelični rak pljuč lokalno napredovali rak pljuč kemoradioterapija imunoterapija true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-06-10 14:46:24 2024-06-10 14:46:24 2024-06-11 03:36:34 0000-00-00 00:00:00 2018 0 Ljubljana 0 str. 281-288, IV no. 3 Vol. 52 Sep. 2018 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2018-09-01 616.2 1318-2099 10.1515/raon-2018-0009 2855035 https://content.sciendo.com/view/journals/raon/52/3/article-p281.xml 1 73e3e90c-2727-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26220 RAZ_Vrankar_Martina_2018.pdf RAZ_Vrankar_Martina_2018.pdf 1 258A46BB0F281F730951D019F87BF34B 33631fa00e8c6b32a92d7948a5d0eb93d455d43986118b6334f2a21bc2e0b4b3 9e6c91de-2727-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26221 Onkološki inštitut Ljubljana 0 0 0